<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688216</url>
  </required_header>
  <id_info>
    <org_study_id>2020-408</org_study_id>
    <nct_id>NCT04688216</nct_id>
  </id_info>
  <brief_title>Developing a Risk Assessment System of Multidrug-resistant Organisms Infection</brief_title>
  <official_title>Developing the Best Risk Assessment System of Multidrug-resistant Organisms Infection in Critically Ill Patients Based on Big Data Analysis Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. A retrospective analysis was performed to determine the prevalence of multidrug-&#xD;
           resistant organisms infection in ICU from October 2017 to October 2019.&#xD;
&#xD;
        2. Non-MDRO patients were selected by random sampling in a ratio of 1:1 to the final MDRO&#xD;
           group during the same period , and select the risk factors of infection with multi-drug&#xD;
           resistant bacteria by comparing the two groups.&#xD;
&#xD;
        3. Randomly select 30% of the sample size as the validation set, and the remaining 70% for&#xD;
           the training set to establish a model. Using multi-factor Logistic regression, decision&#xD;
           tree classification, artificial neural network, support vector machine, Bayesian network&#xD;
           Method to establish risk assessment system for multidrug-resistant organisms infection&#xD;
           respectively.Using validation set data to calculate the area under the ROC curve (AUC)&#xD;
           and sensitivity, specificity of models and comparing the prediction accuracy of several&#xD;
           models. Finally, choose a more suitable risk assessment system for multidrug-resistant&#xD;
           organisms infection.&#xD;
&#xD;
        4. Predict the patient's infection risk level according to the best risk assessment system&#xD;
           and develop a low-to-high intervention plan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Whether multidrug-resistant organisms infection</measure>
    <time_frame>From date of ICU admissions until the date of ICU discharge or date of diagnosis of multidrug-resistant organisms infection , whichever came first, assessed up to 24 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">917</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>MDRO</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-MDRO</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>risk factors of infection with multidrug-resistant organisms</intervention_name>
    <description>General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.&#xD;
Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.&#xD;
The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs</description>
    <arm_group_label>MDRO</arm_group_label>
    <arm_group_label>Non-MDRO</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ①Length of stay in ICU is more than 48h; ② no less than 18 years old.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ①Length of stay in ICU is more than 48h; ② no less than 18 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ①Patients with MDRO infection at the time of admission; ②Inpatient time in ICU &lt;48h;&#xD;
             ③Lack of case data; ④ MDRO colonized patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qian Li, Master</last_name>
    <phone>18329167071</phone>
    <email>2515210@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zexin Chen, doctor</last_name>
      <phone>+86 0571 87783759</phone>
      <email>keyanlunli_zheer@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 6, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>risk assessment system</keyword>
  <keyword>multidrug-resistant organisms</keyword>
  <keyword>ICU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

